NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety and efficacy of expanded activated autologous NK cells
administered after Trastuzumab in patients with HER2-positive breast or gastric cancer. It
will also provide valuable insights of the role of NK cell infusions in adult solid tumors.